arrow_back Back to App

COVID-19 Supplemental Funding and Financial Adjustments

This act allocates billions of additional dollars for coronavirus response, including vaccines, treatments, and research. Simultaneously, some unspent funds from previous programs, such as aid for farmers or small businesses, will be rescinded and returned to the Treasury. Citizens can expect improved access to COVID-19 medical supplies, but also changes in the availability of certain aid programs.
Key points
10.6 billion dollars for COVID-19 vaccines, therapeutics, and research, with a focus on emerging variants.
4.45 billion dollars for global health programs and humanitarian aid related to the pandemic.
Unspent funds from various aid programs (e.g., agriculture, small business, education, transportation) will be returned to the Treasury.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7007
Sponsor: Rep. DeLauro, Rosa L. [D-CT-3]
Process start date: 2022-03-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

COVID Supplemental Appropriations Act, 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7007.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-09.

What are the main provisions?

Key points include:

  • 10.6 billion dollars for COVID-19 vaccines, therapeutics, and research, with a focus on emerging variants.
  • 4.45 billion dollars for global health programs and humanitarian aid related to the pandemic.
  • Unspent funds from various aid programs (e.g., agriculture, small business, education, transportation) will be returned to the Treasury.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. DeLauro, Rosa L. [D-CT-3].

What is the latest detailed status?

The latest detailed status is: Rule H. Res. 973 passed House.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Public Investments Economy